Revolution Medicines, Inc.
NASDAQ:RVMDBiotechnology
+$3.60 today
- Market cap
- $34.57B
- Beta
- 1.41
- P/E (TTM)
- -23.3
- EPS (TTM)
- -$6.92
Volume 2.34M
Average 3.10M
RVMD EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Revolution Medicines, Inc.NASDAQ: RVMD
EPS (Diluted) · Q2 FY2026 · quarter ended Jun 2026
EPS (Diluted) remains negative
Q2 FY2026 EPS (Diluted) was -$3.06, compared with -$1.31 a year earlier. Trailing-twelve-month EPS (Diluted) was -$8.86.
Context
- EPS (Diluted) grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 18 analysts of -$8.44 (-41.8%) for the fiscal year ending Dec 2026, a step up from the -66.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$3.06-33.6% QoQ
- Last fiscal yearDec 2025
- -$5.95-66.2% YoY
- LTMJun 2026
- -$8.86-96.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -133.6% | -45.7% | +87.9 pp |
| 1 year | -66.2% | -41.8% | +24.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (5.95) USD
- Year-over-year change
- -66.2%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.95) | -66.2% |
| FY2024 | 2024-12-31 | (3.58) | +7.3% |
| FY2023 | 2023-12-31 | (3.86) | -25.3% |
| FY2022 | 2022-12-31 | (3.08) | -24.7% |
| FY2021 | 2021-12-31 | (2.47) | — |
EPS (Diluted) vs competitors
How RVMD compares with its peers on the latest reported figures
- RVMD's LTM Jun 2026 EPS (Diluted) of -$8.86 is the lowest of the 11 companies compared; the peer median is -$1.51.
- Its year-over-year change of -96.5% is the 8th highest of 11, against a peer median of +14.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Aug 2026 | $2.31 | +177.8% | — | |
| LTM Mar 2026 | -$0.76 | -1366.7% | — | |
| LTM Sep 2026 | -$0.99 | -120.0% | — | |
| LTM Sep 2026 | -$1.38 | -51.6% | — | |
| LTM Mar 2026 | -$1.44 | +23.0% | — | |
| LTM Jun 2026 | -$1.57 | +19.5% | — | |
| LTM Mar 2026 | -$1.6 | +55.4% | — | |
| LTM Sep 2026 | -$1.68 | +8.7% | — | |
| LTM Mar 2026 | -$1.86 | -2757.1% | — | |
| LTM Mar 2026 | -$2.73 | +23.5% | — | |
| LTM Jun 2026 | -$8.86 | -96.5% | — | |
| Peer median (excluding RVMD) | -$1.51 | +14.1% | — | |
Competitors are the stored peer set for RVMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 29.39M | 35.38M | 11.58M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 16.56M |
| Gross Profit | 29.39M | 35.38M | 11.58M | 0 | (16.56M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 186.95M | 253.07M | 423.14M | 592.23M | 978.68M |
| Selling, General & Admin | 30.45M | 40.59M | 75.62M | 97.3M | 187.13M |
| Operating Expenses | 217.4M | 293.66M | 498.77M | 689.52M | 1.17B |
| Depreciation & Amortization | 7.33M | 9.66M | 9.31M | 11.82M | 16.56M |
| EBITDA | (179.75M) | (239.47M) | (430.28M) | (589.02M) | (1.09B) |
| EBITDA Margin | -611.6% | -676.8% | -3715.7% | — | — |
| Operating Income | (188.01M) | (258.28M) | (487.19M) | (689.52M) | (1.18B) |
| Operating Margin | -639.7% | -730.0% | -4207.1% | — | — |
| Interest Income | 929K | 9.15M | 47.48M | 86.88M | 90.69M |
| Interest Expense | 12K | 0 | 303K | 0 | 24.23M |
| Other Income / Expenses | 917K | 9.15M | 47.29M | 88.68M | 51.07M |
| Income Before Tax | (187.09M) | (249.13M) | (439.89M) | (600.85M) | (1.13B) |
| Pre-Tax Margin | -636.6% | -704.1% | -3798.7% | — | — |
| Income Tax Expense | 0 | (420K) | (3.52M) | (753K) | 0 |
| Net Income | (187.09M) | (248.71M) | (436.37M) | (600.09M) | (1.13B) |
| Net Margin | -636.6% | -703.0% | -3768.3% | — | — |
| EPS (Basic) | (2.47) | (3.08) | (3.86) | (3.58) | (5.95) |
| EPS (Diluted) | (2.47) | (3.08) | (3.86) | (3.58) | (5.95) |
| Weighted Avg Shares | 72.81M | 80.63M | 113.15M | 167.74M | 190.13M |
| Weighted Avg Shares (Diluted) | 72.81M | 80.63M | 113.15M | 167.74M | 190.13M |
Revolution Medicines, Inc.
NASDAQ:RVMD
Intrinsic Alpha fair value
Locked
Current Price
$159.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.